Enovix (ENVX) Projected to Post Earnings on Wednesday

Enovix (NASDAQ:ENVX) is expected to be posting its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Enovix to post earnings of ($0.17) per share and revenue of $10.2490 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

Enovix Stock Performance

Enovix stock opened at $5.95 on Monday. Enovix has a fifty-two week low of $5.27 and a fifty-two week high of $16.49. The firm’s 50 day simple moving average is $7.28 and its 200-day simple moving average is $9.04. The company has a debt-to-equity ratio of 1.74, a current ratio of 9.72 and a quick ratio of 9.47. The company has a market cap of $1.28 billion, a P/E ratio of -7.35 and a beta of 2.13.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ENVX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Enovix by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 98,318 shares of the company’s stock worth $722,000 after purchasing an additional 4,780 shares during the last quarter. NewEdge Advisors LLC increased its holdings in Enovix by 10.4% in the first quarter. NewEdge Advisors LLC now owns 26,257 shares of the company’s stock worth $193,000 after buying an additional 2,481 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Enovix by 65.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,137,777 shares of the company’s stock worth $8,351,000 after buying an additional 449,934 shares during the last quarter. Caxton Associates LLP bought a new position in Enovix during the first quarter valued at approximately $190,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Enovix by 18.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 358,023 shares of the company’s stock valued at $2,628,000 after acquiring an additional 55,676 shares during the last quarter. Hedge funds and other institutional investors own 50.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Cantor Fitzgerald cut their target price on shares of Enovix from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Northland Securities set a $16.00 price target on Enovix in a report on Monday, November 17th. Oppenheimer set a $24.00 price objective on Enovix in a research note on Thursday, November 6th. JPMorgan Chase & Co. decreased their price objective on Enovix from $12.00 to $10.00 and set a “neutral” rating for the company in a research report on Wednesday, November 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovix in a research note on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Enovix presently has a consensus rating of “Hold” and a consensus price target of $17.50.

About Enovix

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.